Related Experiment Video

Updated: Jul 12, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

[Current situation of researches on the molecule mechanism of hormone refractory prostate cancer]

Nian-qin Yang1, Yi-xin Wang

  • 1Department of Urology, Renji Hospital, Shanghai Second Medical University, Shanghai Institute of Andrology, Shanghai 200001, China.

Zhonghua Nan Ke Xue = National Journal of Andrology
|July 13, 2006
PubMed

Insights

Prostate cancer often becomes hormone refractory due to multifactorial causes. This review explores molecular mechanisms involving androgen receptor, apoptosis, and specific gene changes in refractory prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Context:

  • Prostate cancer frequently develops hormone resistance after androgen deprivation therapy.
  • Understanding the molecular basis of hormone refractory prostate cancer is crucial for treatment development.

Purpose:

  • To review current research on the molecular mechanisms of hormone refractory prostate cancer.
  • To elucidate the roles of androgen receptor signaling, apoptosis, and key genes (p53, p21, EphB2) in treatment resistance.

Summary:

  • Hormone refractory prostate cancer emerges after androgen deprivation therapy, influenced by genetic, dietary, and environmental factors.
  • Key molecular mechanisms include androgen receptor mutations, altered apoptosis pathways, and changes in tumor suppressor genes like p53 and p21, as well as EphB2.
  • This review synthesizes domestic and international research on these molecular underpinnings.

Impact:

  • Provides insights into the molecular drivers of treatment resistance in prostate cancer.
  • Offers potential targets for novel therapeutic strategies against hormone refractory prostate cancer.
  • Aims to guide future research in understanding and overcoming prostate cancer progression.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: